Importantly, these findings should not be extrapolated to newer dual incretin agonists such as tirzepatide
Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents
Potential Negatives There may be concerns regarding the dependency on GLP-1 medications, as the press release emphasizes the need for combined treatment with medication and behavioral support, which could raise questions about the sustainability of the weight loss achieved
It has real implications for treatment outcomes, side effects, quality of life, and long-term health
This multi-disciplinary support ensures that every aspect of your health and well-being is addressed, making sustainable weight loss achievable
If you have a history of gallbladder disease or gallstones, discuss this with your prescriber before starting